Real-World Comparative Effectiveness of First-Line Alectinib Versus Crizotinib in Patients With Advanced ALK-Positive NSCLC With or Without Baseline Central Nervous System Metastas... by Zhang, Qing, PhD, Lin, Jessica J., MD, Pal, Navdeep, M.B.B.S., MPH, Polito, Letizia, PhD, Trinh, Huong, MD, Hilton, Magalie, MSc, Smoljanović, Vlatka, MD, Kurtsikidze, Nino, MD, Archer, Venice, MD, Krebs, Matthew G., MD, PhD

Get full text

Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatm... by Noé, Johannes, PhD, Bordogna, Walter, PhD, Archer, Venice, MD, Smoljanovic, Vlatka, MD, Hilton, Magalie, MSc, Woodhouse, Ryan, BSc, Mocci, Simonetta, MD, PhD, Gadgeel, Shirish M., MD

Get full text

Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study by Zhou, Caicun, Lu, You, Kim, Sang-We, Reungwetwattana, Thanyanan, Zhou, Jianying, Zhang, Yiping, He, Jianxing, Yang, Jin-Ji, Cheng, Ying, Lee, Se-Hoon, Chang, Jianhua, Fang, Jian, Liu, Zhe, Bu, Lilian, Qian, Li, Xu, Tingting, Archer, Venice, Hilton, Magalie, Zhou, Mingzhu, Zhang, Li

Get full text